PALO ALTO, Calif., April 7, 2008 /PRNewswire-FirstCall/ -- Telik, Inc.
(Nasdaq: TELK) announced that four abstracts highlighting results from its
Research and Development programs will be presented at the 99th annual
meeting of the American Association for Cancer Research (AACR) in San
Details of the presentations are as follows:
-- Identification and Characterization of Novel Tyrosine Kinase Inhibitors
Targeting Vascular Endothelial Growth Factor Receptor 2; Sunday, April
13, 2008, 1:00 - 5:00pm; Experimental and Molecular Therapeutics 10;
Abstract # 1439
-- Mechanism of Induction of Apoptosis by TLK199 (Telintra(R)) in Human
Leukemia Cell Lines; Monday, April 14, 2008, 8:00am - 12noon;
Experimental and Molecular Therapeutics 10; Abstract # 2270
-- Identification of a Novel Class of Nonpeptidyl Small-Molecule
Inhibitors of the Human Proteasome; Monday, April 14, 2008,
1:00 - 5:00pm; Experimental and Molecular Therapeutics 28;
Abstract # 3271
-- Target-Related Affinity Profiling (TRAP(R)): Efficient Cancer Drug
Discovery at Telik; Tuesday, April 15, 2008; 1:00 - 5:00pm; Cancer
Chemistry 11; Abstract # 4754
Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates.
TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc.
|SOURCE Telik, Inc.|
Copyright©2008 PR Newswire.
All rights reserved